TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03269175

Intervention type: OTHER
Group type: OTHER
Intervention: Brain MRI
Description: Brain MRI will be performed

Intervention type: OTHER
Group type: OTHER
Intervention: Brain MRI
Description: Brain MRI will be performed

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Blood samples will be taken
Study: NCT02810626

Intervention type: DEVICE
Group type: OTHER
Intervention: BrightMatter™ products
Description: BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively.
Study: NCT03302559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: Sunscreen broad spectrum sun protection factor (SPF) 35 topically in the morning and as needed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Imaging
Description: Non-invasive in vivo skin imaging will be taken with the VivoSight Dx Optical Coherence Tomography (OCT) and VivaScope 1500
Study: NCT03269175

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Blood samples will be taken
Study: NCT00676585

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 100mg
Study: NCT05017493

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Xagrotin
Description: A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care
Study: NCT04295499

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: soft (hydrophilic) contact lens
Description: The intervention is a daily wear soft contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft (hydrophilic) contact lens
Description: The intervention is a daily wear soft contact lens
Study: NCT00563433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ofloxacin
Description: 400 mg twice a day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSI-78
Description: 1%/2% topical cream twice a day for 14 days
Study: NCT03100253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: a. Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: infliximab if initial failure to the receptor fusion protein, etanercept.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: adalimumab if initial failure to the receptor fusion protein, etanercept.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab
Description: golimumab if initial failure to the receptor fusion protein, etanercept.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab Pegol
Description: Certolizumab Pegol if initial failure to the receptor fusion protein, etanercept.
Study: NCT00689663

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Randomized to three arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Randomized to three arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Randomized to three arm.
Study: NCT01094366

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical Block
Description: Subject receives 20 mL paracervical block with 18 mL of 1% Lidocaine solution buffered with 2 mL 8.4% sodium bicarbonate for pain control.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Paracervical Block
Description: In the non-intervention group, the surgeon performs a sham PCB during which 2 mL buffered lidocaine solution are injected at the tenaculum site, after which a capped needle gently simulates the standard PCB procedure.
Study: NCT04714099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Cyclosporine A
Description: In our study we used 0.05% CsA prepared in castor oil by transferring (20ml ) of sterile castor oil in a sterile glass vial under laminar flow, removing a volume (400ul)of oil with micropipette (sterile tips), and replacing this volume with an equal volume of alcoholic CsA solution \[200mg cyclosporine in 8 ml ethanol (96%)\] under laminar flow.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02971605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 25 mg/70 kg Psilocybin
Study: NCT00437281

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Orally-administered pregabalin
Study: NCT03244995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mind-Body Intervention Procedure
Description: Undergo CBMB program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04036578

Intervention type: DEVICE
Group type: OTHER
Intervention: A 12-week PFMT bio-assisted surface electromyographic program
Study: NCT03875391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Drug: Oxytocin nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo nasal spray
Study: NCT02915510

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycomacropeptide-based protein substitute
Study: NCT03635684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Subcutaneous infusion of Acetaminophen over 20 to 30 minutes, with evaluation of:~* local side effects;~* pain and/or fever;~at time of infusion, after 30 minutes, 60 minutes and 180 minutes.
Study: NCT02613065

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of NOW Foods eggwhite protein shake
Description: Consumption of NOW Foods egg white protein shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of NOW Foods maltodextrin shake
Description: Consumption of NOW Foods maltodextrin shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
Study: NCT02261571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: In the moxibustion treatment group, 3 moxibustion, 3 acupoints(CV12, CV8, CV54) will be heated with indirected moxibustion.~The moxibustion will be removed when the patient feel hotness and require remove them
Study: NCT02022371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted biopsies of the prostate
Description: Multiple biopsies from a MRI lesion for analysis of intratumour heterogeneity
Study: NCT03973996

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Tea Extract
Description: A gummy confection with catechin-rich green tea extract (1 g/d)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched gummy confection formulated without green tea extract
Study: NCT04400695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel Injection
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel Injection
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine Tartrate Injection
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine Tablets
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study: NCT04128449

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid
Description: 5 dragees every 24 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 dragees every 24 hours
Study: NCT03760510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tube Fastener
Description: Endotrachel tube secured with tube fastener

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhesive Tape
Description: Endotracheal tube secured with adhesive tape.
Study: NCT01491659

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Idoform Plus
Description: orally once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally once daily
Study: NCT01488019

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perforomist-Placebo
Description: Placebo vehicle, 2mL, twice daily for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perforomist, nebulization, COPD
Description: Perforomist, 20 mcg/2 mL, twice daily for 52 weeks
Study: NCT04235647

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nurse led tutorial on lifestyle management and pedometer hand-out
Description: Individual 10-minute nurse-led tutorial with distributed handouts on the health benefits of regular physical activity and pedometer hand-out

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse led tutorial on lifestyle management and pedometer hand-out
Description: Individual 10-minute nurse-led tutorial with distributed handouts on the health benefits of regular physical activity and pedometer hand-out

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steps goal setting and supporting phone calls
Description: A goal of minimum 7000 steps per day, phone calls to assess the goal meeting and to support goal achievement every 2 weeks
Study: NCT01332110

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Knee abduction moment-reducing footwear
Description: Patients in each study group will be asked to run using their assigned footwear at least 3 times per week (minimum 15 km per week) for six weeks. Each patient will document their perceived knee pain each week throughout the six week intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee abduction moment-reducing footwear
Description: Patients in each study group will be asked to run using their assigned footwear at least 3 times per week (minimum 15 km per week) for six weeks. Each patient will document their perceived knee pain each week throughout the six week intervention.
Study: NCT03682783

Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus Image
Description: Fundus image of optic nerve
Study: NCT00235833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg every other week (eow), subcutaneous (sc)
Study: NCT01344395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine and ketorolac
Description: The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively
Study: NCT03982082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Undergo physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound via MuscleSound technology
Study: NCT05531994

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium oral thin films with water (T)
Description: Single-dose montelukast sodium oral thin film 5mg under fed condition with water 240 mL

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium oral thin films with water (T)
Description: Single-dose montelukast sodium oral thin film 5mg under fed condition with water 240 mL

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium chewable tablets with water (R)
Description: Single-dose montelukast sodium chewable tablet 5mg under fed condition with water 240 mL

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium chewable tablets with water (R)
Description: Single-dose montelukast sodium chewable tablet 5mg under fed condition with water 240 mL
Study: NCT00360308

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00926289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Telmisartan 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide25mg
Study: NCT02734615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSZ102
Description: LSZ102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSZ102
Description: LSZ102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSZ102
Description: LSZ102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSZ102
Description: LSZ102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSZ102
Description: LSZ102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSZ102
Description: LSZ102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSZ102
Description: LSZ102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719
Study: NCT04537325

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RenalGuard system
Description: Periprocedural intravenous hydration matched to urinary output.
Study: NCT04571957

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT00780715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide MR
Description: 30mg daily increased to 60mg if HbA1c \> 7% at 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100mg daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30mg daily , increased to 45mg daily if HbA1c \>7% at 3 months. 6 months duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment
Study: NCT01950754

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standing with both feet

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standing with both feet

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: descent of the platform

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: descent of the platform

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standing on the platform, feet together and always with simultaneous performance of a task of mental count

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standing on the platform, feet together and always with simultaneous performance of a task of mental count
Study: NCT00756028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients receiving short protocol IVF/ICSI-treatment.
Description: Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long protocol
Description: Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
Study: NCT04447833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205
Description: Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs).
Study: NCT00111189

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every 4 wk up to 24 mo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate
Description: 25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
Study: NCT03221946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: tablet of 50mg,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: Transdermal patch 100 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Diclofenac
Description: intra muscular injection 100mg
Study: NCT00583596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device closure with AMPLATZER Duct Occluder
Description: Device closure with AMPLATZER Duct Occluder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Objective Performance Criteria
Description: Compare results of device closure to objective performance criteria
Study: NCT04318652

Intervention type: DRUG
Group type: OTHER
Intervention: Methylprednisolone eyedrops
Description: instillation of methylprednisolone eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone eyedrops
Description: instillation of methylprednisolone eye drops
Study: NCT01933828

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OPEN lobectomy
Description: Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS lobectomy
Description: Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.

Intervention type: DEVICE
Group type: OTHER
Intervention: ROBOT-assisted lobectomy
Description: Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
Study: NCT03509051

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B vaccination
Description: One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
Study: NCT04317729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fujirebio INNOTEST® HCV Ab IV assay
Description: Enzyme Immunoassay
Study: NCT02888925

Intervention type: OTHER
Group type: OTHER
Intervention: Mooney test

Intervention type: OTHER
Group type: OTHER
Intervention: Mooney test

Intervention type: OTHER
Group type: OTHER
Intervention: Benton Face Recognition test

Intervention type: OTHER
Group type: OTHER
Intervention: Benton Face Recognition test

Intervention type: OTHER
Group type: OTHER
Intervention: Face inversion effect test

Intervention type: OTHER
Group type: OTHER
Intervention: Face inversion effect test

Intervention type: OTHER
Group type: OTHER
Intervention: Face composite effect test

Intervention type: OTHER
Group type: OTHER
Intervention: Face composite effect test

Intervention type: OTHER
Group type: OTHER
Intervention: Cambridge Face Memory Test

Intervention type: OTHER
Group type: OTHER
Intervention: Cambridge Face Memory Test
Study: NCT05606640

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsychological pain assessment
Description: At baseline (T0) patients underwent the somatosensory pain assessment, joint structure and function assessment and filled in all questionnaires. During one month after baseline (T1) patients wore an activity tracker and filled in the Illness Perceptions Questionnaire and the International Physical Activity questionnaire. During one year after the baseline assessment (T2) patients filled in every month The Brief Pain Inventory, Illness Perceptions Questionnaire and the EQ-5D-5L quality of life questionnaire.
Study: NCT03916237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home assessment
Description: Home assessment for environmental hazards according to protocol established by Environmental Health Watch (Healthy Home Audit https://www.ehw.org/healthy-home-audit/)
Study: NCT02888925

Intervention type: OTHER
Group type: OTHER
Intervention: Matching different view test

Intervention type: OTHER
Group type: OTHER
Intervention: Matching different view test

Intervention type: OTHER
Group type: OTHER
Intervention: Memorizing and recognition of new faces test

Intervention type: OTHER
Group type: OTHER
Intervention: Memorizing and recognition of new faces test
Study: NCT00360308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2007
Study: NCT02888925

Intervention type: OTHER
Group type: OTHER
Intervention: Memorizing and recognition of new objects test

Intervention type: OTHER
Group type: OTHER
Intervention: Memorizing and recognition of new objects test

Intervention type: OTHER
Group type: OTHER
Intervention: Recognition of celebrities and access to semantic information test

Intervention type: OTHER
Group type: OTHER
Intervention: Recognition of celebrities and access to semantic information test

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lobectomy
Description: In patients with anterior temporal epilepsy, at 6 to 12 months after inclusion, depending on surgery decision taken after pre-surgery conventional intercritical assessment